Epstein-Barr Virus Nuclear Antigen-Positive Nasopharyngeal Hybrid Cells

Takimoto, Toru; Hatano, Miyako; Furukawa, Mitsuru; Umeda, Ryozo

doi:10.1177/000348948409300213

Cited by 33 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29). Ad-AH cells, kindly provided by Dr. Erik K. Flemington (Tulane University), are an EBV-negative human nasopharyngeal epithelial cell line (30). Ad-AH cells were maintained in DMEM with 10% fetal bovine serum, penicillin, and streptomycin.…”

Section: Methodsmentioning

confidence: 99%

Induction of Receptor for Advanced Glycation End Products by EBV Latent Membrane Protein 1 and Its Correlation with Angiogenesis and Cervical Lymph Node Metastasis in Nasopharyngeal Carcinoma

Tsuji

Wakisaka

Kondo

et al. 2008

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Purpose: The EBV oncoprotein, latent membrane protein 1 (LMP1), contributes to the metastasis of nasopharyngeal carcinoma (NPC) by inducing factors to promote tumor invasion and angiogenesis. The receptor for advanced glycation end products (RAGE) is associated with abnormal angiogenesis in diabetic microangiopathies. Moreover, some papers have suggested the association of RAGE overexpression with tumor metastasis; thus, the associations of RAGE with LMP1and angiogenesis in NPC were examined. Experimental Design: Forty-two patients with NPC were evaluated for expressions of LMP1, RAGE, and S100 proteins and for microvessel counts by immunohistochemistry. Then, the RAGE induction by LMP1was examined with Western blotting and luciferase reporter assay. Results: The microvessel counts were significantly higher in patients with high LMP1expression or high RAGE expression compared with cases with low expressions (P = 0.0049 and P < 0.0001), respectively. Patients with advanced N classification were also significantly increased in these groups (P = 0.0484 and P = 0.0005). The expressions of LMP1 and RAGE proteins were clearly correlated in NPC tissues (P = 0.0093). Transient transfection with LMP1 expression plasmid induced RAGE protein in Ad-AH cells.The expression of LMP1 transactivated the RAGE promoter as shown by luciferase reporter assay. Mutation of the reporter at nuclear factor-nB binding site (-671to -663) abolished transactivation of the RAGE promoter by LMP1. Conclusion: These results suggest that LMP1-induced RAGE enhances lymph node metastasis through the induction of angiogenesis in NPC. Nuclear factor-nB binding site (-671 to -663) is essential for transactivation of the RAGE promoter by LMP1.

show abstract

Section: Methodsmentioning

confidence: 99%

Induction of Receptor for Advanced Glycation End Products by EBV Latent Membrane Protein 1 and Its Correlation with Angiogenesis and Cervical Lymph Node Metastasis in Nasopharyngeal Carcinoma

Tsuji

Wakisaka

Kondo

et al. 2008

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ad-AH cells, kindly provided by Erik K. Flemington (Tulane University, New Orleans, La. ), are an EBV-negative human nasopharyngeal cell line (58). Human embryonic kidney 293 cells and HeLa cells were obtained from the American Type Culture Collection.…”

Section: Cell Cultures Kr-4 Is An Ebv-positive Type III Lymphoblastomentioning

confidence: 99%

Epstein-Barr Virus Latent Membrane Protein 1 Induces Synthesis of Hypoxia-Inducible Factor 1α

Wakisaka

Kondo

Yoshizaki

et al. 2004

Molecular and Cellular Biology

Self Cite

219

214

View full text Add to dashboard Cite

. Moreover, LMP1 induces HIF-1 DNA binding activity and upregulates HRE and VEGF promoter transcriptional activity. Finally, LMP1 increases the appearance of VEGF protein in extracellular fluids; induction of VEGF is suppressed by PD98059 or catalase. These results suggest that LMP1 increases HIF-1 activity through induction of HIF-1␣ protein expression, which is controlled by p42/p44 MAPK activity and H 2 O 2 . The ability of EBV, and specifically its major oncoprotein, LMP1, to induce HIF-1␣ along with other invasiveness and angiogenic factors reported previously discloses additional oncogenic properties of this tumor virus.

show abstract

“…When the authors could not find any vessel structure highlighted in the tumor stroma, the specimen was considered A pcDNA3-based LMP1-expression plasmid (pcLMP1) has been described previously [23] . Ad-AH cells are an EBV-negative human nasopharyngeal epithelial cell line [24] . Cells were maintained in DMEM with 10% fetal bovine serum, penicillin, and streptomycin.…”

Section: Introductionmentioning

confidence: 99%

Induction of lymphangiogenesis through vascular endothelial growth factor-C/vascular endothelial growth factor receptor 3 axis and its correlation with lymph node metastasis in nasopharyngeal carcinoma

et al. 2012

View full text Add to dashboard Cite

Objectives: The contribution of the lymphatic system to tumor metastasis is being increasingly appreciated through studies of human cancers. As the biological behavior of nasopharyngeal carcinoma (NPC) depends on its nodal status, patients with advanced nodal status show a higher tendency toward a poor outcome. Here, we examined the role of lymphangiogenesis on lymphatic spread of NPC. We also evaluated

show abstract

Epstein-Barr Virus Nuclear Antigen-Positive Nasopharyngeal Hybrid Cells

Cited by 33 publications

References 18 publications

Induction of Receptor for Advanced Glycation End Products by EBV Latent Membrane Protein 1 and Its Correlation with Angiogenesis and Cervical Lymph Node Metastasis in Nasopharyngeal Carcinoma

Induction of Receptor for Advanced Glycation End Products by EBV Latent Membrane Protein 1 and Its Correlation with Angiogenesis and Cervical Lymph Node Metastasis in Nasopharyngeal Carcinoma

Epstein-Barr Virus Latent Membrane Protein 1 Induces Synthesis of Hypoxia-Inducible Factor 1α

Induction of lymphangiogenesis through vascular endothelial growth factor-C/vascular endothelial growth factor receptor 3 axis and its correlation with lymph node metastasis in nasopharyngeal carcinoma

Contact Info

Product

Resources

About